The GLP-1 Paradox: When Weight Loss Becomes the Goal Instead of Better Health
There is a peculiar irony unfolding in modern medicine. We finally have powerful tools capable of helping many people lose substantial amounts of weight—and now the conversation is beginning to evolve into a much more important question:
What exactly are we losing?
GLP-1–based medications have become one of the defining health trends of 2026. Semaglutide and tirzepatide have changed the conversation around obesity, diabetes, cardiometabolic disease, and weight management. Their effects can be significant, and for many patients, these medications may offer meaningful health benefits. So let me say something that may surprise people:
GLP-1 medications are not the problem.
The problem begins when we confuse the number on the scale with the condition of the human being standing on it. Because losing 30 pounds and becoming healthier are not necessarily the same thing. And that distinction may be the missing variable in the GLP-1 conversation.
The Scale Is a Measurement, Not a Medical Report Card
Imagine renovating a house and judging the entire project by how much debris you hauled away. Less debris is certainly progress. But what if you accidentally removed some of the plumbing, insulation, wiring, and structural supports along with it? The house might look cleaner. It might even look dramatically different. But appearance alone doesn’t tell you whether the house functions better.
The same principle applies to weight loss. A scale measures weight. It does not tell you how much of that weight came from fat, lean tissue, water, glycogen, or other components. That matters because muscle isn’t merely something we admire in the mirror. It is metabolically active tissue involved in movement, glucose handling, physical function, and resilience as we age.
Recent reviews of GLP-1–based therapies emphasize this shift in thinking: the quality of weight loss matters, not merely the quantity. Lean mass can decline during weight reduction, although “lean mass” on a body-composition scan is not synonymous with skeletal muscle, and a reduction in lean tissue does not automatically mean a clinically meaningful loss of strength or function. (PubMed)
That distinction is important. We don’t need another reason to fear GLP-1s. We need a better way to use them.
Rooted in Faith. Guided by Nature. Driven by Purpose. Dr. Jill Fandrich brings science and nature together to support wellness with clarity, purpose, and meaningful impact.
To view the forthcoming ClarityRx line, follow this link.